Just joined

Discussion in 'Pharmacyclics' started by anonymous, Mar 25, 2017 at 4:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    only a couple went to beigene, no one went to blueprint, no one went to gsk, no one yet went to abbvie. this is a great job you can coast right into 2021 and everyone knows it
     

  2. anonymous

    anonymous Guest

    Blueprint reps wont start until January so they may be still on board
     
  3. anonymous

    anonymous Guest

    Blueprint in January and Seattle soon too. See at least a few more leaving.
     
  4. anonymous

    anonymous Guest

    Thanks for the quick meeting. I guess not having a pipeline has some benefits.
     
  5. anonymous

    anonymous Guest

    I love Alex and Susan. Stay safe, take care of yourself and your families. Why the fuck are we losing share and you guys arent entering enough calls! Imbruvica had its day and now it will be a slow grind down with all these new managers who are worried they will not get another managers job at another company.
     
  6. anonymous

    anonymous Guest

    Alex is not happy. He figured he would oversee Imbruvicas on cruise control and now that it is losing steam to Venetoclax and Acala he wants us to be bold! The next year will be a tough one.
     
  7. anonymous

    anonymous Guest

    Imbruvica was a great drug but that was in the past. If you are here and are not looking to ride out the last couple years of your career, you should be looking. Companies dont take it well when their key drug falters and there will be three options: 1. They ride you to try to overcome the data yet dont pay you 2. they get absorbed by Abbvie and you go there in a very weak state 3. the put people on plan and force you out.

    Maybe all three. Time to leave PCYC